<DOC>
	<DOCNO>NCT01099319</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Renalof administration treatment gallstone ( cholelithiasis ) determine ultrasonography clinical evaluation elderly patient ( age &gt; 65 year ) . The duration double-blind placebo control phase 3 clinical trial 6 month . The estimated number patient recruit randomized study 40 .</brief_summary>
	<brief_title>Renalof Treatment Elderly Patients With Gallstones</brief_title>
	<detailed_description />
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Cholelithiasis</mesh_term>
	<mesh_term>Cholecystolithiasis</mesh_term>
	<criteria>Confirmation cholelithiasis ultrasonography without clinical symptom . Signed informed consent Previous surgical intervention treatment cholelithiasis Cholelithiasis acute symptom require emergency surgery Cholelithiasis associate neoplastic condition localization origin Usage antioxidant within duration clinical trial Handicap and/or psychiatric condition prevent treatment accomplishment</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Renalof</keyword>
	<keyword>gallstone</keyword>
	<keyword>elderly</keyword>
</DOC>